Stock listing
Euronext:ALIKO Ikonisys SA Action
Home listing (Euronext) of Ikonisys SA
Follow Ikonisys SA into a list and get an email when it puts out news.
Share price · EURONEXT:ALIKO
€1.54 EUR +0.16 (+11.6%)
Close on Nov 20, 2026
- Day range
- €1.47 – €1.54 EURNov 20, 2026
- Volume
- 2,712 sharesNov 20, 2026
- Market cap
- €24.37M EURAt the close on Nov 20, 2026 · price × 15.83M shares outstanding
- 52-week range
- €1.30 – €1.84 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3,685 EURMedian day 1,784 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:ALIKO · Home | €1.54 EUR | +0.16 (+11.6%) | 2,712 | €1.47 | €1.54 | €1.47 | €1.38 | Close on Nov 20, 2026 |
| Frankfurt:9W8 | €1.37 EUR | +0.03 (+2.2%) | — | €1.37 | €1.37 | €1.37 | €1.34 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:ALIKO · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.54 | +0.16 | +11.6% | €1.47 | €1.54 | €1.47 | 2,712 | |
| €1.38 | -0.07 | -4.8% | €1.46 | €1.46 | €1.38 | 2,430 | |
| €1.45 | -0.01 | -0.7% | €1.45 | €1.45 | €1.45 | 957 | |
| €1.46 | +0.01 | +0.7% | €1.44 | €1.46 | €1.41 | 6,143 | |
| €1.45 | 0.00 | 0.0% | €1.45 | €1.45 | €1.39 | 1,613 | |
| €1.45 | +0.04 | +2.8% | €1.40 | €1.45 | €1.40 | 2,754 | |
| €1.41 | 0.00 | 0.0% | €1.41 | €1.41 | €1.41 | 5 | |
| €1.41 | 0.00 | 0.0% | €1.41 | €1.42 | €1.39 | 344 | |
| €1.41 | +0.01 | +0.7% | €1.40 | €1.41 | €1.36 | 410 | |
| €1.40 | 0.00 | 0.0% | €1.40 | €1.40 | €1.40 | 6 | |
| €1.40 | -0.01 | -0.7% | €1.40 | €1.40 | €1.40 | 6 | |
| €1.41 | +0.01 | +0.7% | €1.39 | €1.41 | €1.39 | 88 | |
| €1.40 | -0.01 | -0.7% | €1.41 | €1.42 | €1.38 | 637 | |
| €1.41 | -0.01 | -0.7% | €1.42 | €1.42 | €1.41 | 232 | |
| €1.42 | -0.01 | -0.7% | €1.42 | €1.42 | €1.42 | 44 | |
| €1.43 | +0.03 | +2.1% | €1.40 | €1.45 | €1.40 | 3,334 | |
| €1.40 | +0.07 | +5.3% | €1.35 | €1.41 | €1.35 | 1,947 | |
| €1.33 | -0.05 | -3.6% | €1.36 | €1.36 | €1.33 | 6,542 | |
| €1.38 | +0.01 | +0.7% | €1.37 | €1.39 | €1.36 | 2,521 | |
| €1.37 | -0.01 | -0.7% | €1.37 | €1.37 | €1.37 | 168 | |
| €1.38 | -0.03 | -2.1% | €1.35 | €1.41 | €1.35 | 1,482 | |
| €1.41 | 0.00 | 0.0% | €1.40 | €1.41 | €1.35 | 2,314 | |
| €1.41 | -0.02 | -1.4% | €1.43 | €1.43 | €1.36 | 1,777 | |
| €1.43 | 0.00 | 0.0% | €1.41 | €1.43 | €1.41 | 349 | |
| €1.43 | +0.02 | +1.4% | €1.43 | €1.43 | €1.43 | 10 | |
| €1.41 | 0.00 | 0.0% | €1.42 | €1.42 | €1.41 | 190 | |
| €1.41 | -0.03 | -2.1% | €1.42 | €1.42 | €1.41 | 190 | |
| €1.44 | +0.02 | +1.4% | €1.42 | €1.44 | €1.42 | 303 | |
| €1.42 | +0.02 | +1.4% | €1.42 | €1.42 | €1.42 | 445 | |
| €1.40 | -0.04 | -2.8% | €1.42 | €1.42 | €1.40 | 2,001 | |
| €1.44 | +0.01 | +0.7% | €1.42 | €1.44 | €1.42 | 305 | |
| €1.43 | -0.01 | -0.7% | €1.43 | €1.43 | €1.43 | 1,010 | |
| €1.44 | -0.01 | -0.7% | €1.44 | €1.45 | €1.43 | 4,177 | |
| €1.45 | -0.02 | -1.4% | €1.46 | €1.46 | €1.44 | 3,288 | |
| €1.47 | +0.02 | +1.4% | €1.44 | €1.47 | €1.40 | 11,547 | |
| €1.45 | +0.05 | +3.6% | €1.40 | €1.45 | €1.35 | 13,490 | |
| €1.40 | -0.01 | -0.7% | €1.41 | €1.41 | €1.40 | 3,136 | |
| €1.41 | -0.02 | -1.4% | €1.42 | €1.42 | €1.41 | 2,689 | |
| €1.43 | +0.01 | +0.7% | €1.42 | €1.43 | €1.42 | 810 | |
| €1.42 | 0.00 | 0.0% | €1.41 | €1.43 | €1.41 | 5,112 | |
| €1.42 | +0.01 | +0.7% | €1.41 | €1.42 | €1.41 | 569 | |
| €1.41 | -0.01 | -0.7% | €1.41 | €1.41 | €1.41 | 205 | |
| €1.42 | 0.00 | 0.0% | €1.41 | €1.42 | €1.41 | 1,079 | |
| €1.42 | +0.04 | +2.9% | €1.40 | €1.42 | €1.40 | 5,931 | |
| €1.38 | -0.02 | -1.4% | €1.39 | €1.39 | €1.38 | 1,791 | |
| €1.40 | 0.00 | 0.0% | €1.39 | €1.40 | €1.38 | 2,144 | |
| €1.40 | 0.00 | 0.0% | €1.39 | €1.40 | €1.39 | 1,401 | |
| €1.40 | 0.00 | 0.0% | €1.40 | €1.40 | €1.30 | 9,339 | |
| €1.40 | 0.00 | 0.0% | €1.36 | €1.40 | €1.36 | 4,685 | |
| €1.40 | 0.00 | 0.0% | €1.36 | €1.40 | €1.36 | 4,685 | |
| €1.40 | 0.00 | 0.0% | €1.38 | €1.40 | €1.34 | 2,690 | |
| €1.40 | 0.00 | 0.0% | €1.42 | €1.42 | €1.40 | 244 | |
| €1.40 | -0.02 | -1.4% | €1.42 | €1.42 | €1.40 | 244 | |
| €1.42 | +0.02 | +1.4% | €1.42 | €1.42 | €1.42 | 2,500 | |
| €1.40 | -0.02 | -1.4% | €1.40 | €1.40 | €1.40 | 5,201 | |
| €1.42 | 0.00 | 0.0% | €1.42 | €1.42 | €1.41 | 8,028 | |
| €1.42 | -0.06 | -4.1% | €1.48 | €1.48 | €1.40 | 9,005 | |
| €1.48 | -0.04 | -2.6% | €1.50 | €1.50 | €1.48 | 347 | |
| €1.52 | +0.06 | +4.1% | €1.46 | €1.52 | €1.46 | 4,595 | |
| €1.46 | -0.02 | -1.4% | €1.46 | €1.46 | €1.46 | 377 | |
| €1.48 | +0.02 | +1.4% | €1.46 | €1.48 | €1.46 | 514 | |
| €1.46 | +0.04 | +2.8% | €1.42 | €1.46 | €1.42 | 2,737 | |
| €1.42 | -0.04 | -2.7% | €1.44 | €1.44 | €1.40 | 4,735 | |
| €1.46 | -0.08 | -5.2% | €1.52 | €1.52 | €1.42 | 4,146 | |
| €1.54 | +0.02 | +1.3% | €1.54 | €1.54 | €1.52 | 278 | |
| €1.52 | 0.00 | 0.0% | €1.54 | €1.54 | €1.50 | 5,217 |
- Ticker
- Euronext:ALIKO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Euronext
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Aliko Scientific Launches CYTOfast Auto at MEDICA 2026, Expanding Into High-Volume Screening Markets
Latest news
Aliko Scientific Launches CYTOfast Auto at MEDICA 2026, Expanding Into High-Volume Screening Markets
Nov 12, 2026
Closed €1.45 (+2.8%) on Nov 12, 2026
Aliko Scientific announces the results of its Ordinary Annual and Extraordinary General Meeting of October 30, 2026
Nov 5, 2026
Closed €1.40 (-0.7%) on Nov 5, 2026
ALIKO Scientific Announces Settlement of a Dispute Involving Its US Subsidiary, Which Will Receive USD 2 Million
Sep 21, 2026
Closed €1.42 (+2.9%) on Sep 21, 2026
Aliko Scientific Launches Probantes in Brazil and Establishes a New Molecular Diagnostic Development and Commercial Platform for South America
Sep 15, 2026
Closed €1.40 (0.0%) on Sep 15, 2026
Aliko Scientific Successfully Launches U.S. Business Development Collaboration With Partner International at ADLM 2026, the World’s Largest Molecular Diagnostics Exhibition
Sep 7, 2026
Closed €1.40 (-1.4%) on Sep 8, 2026
Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum
Aug 24, 2026
Closed €1.42 (-2.7%) on Aug 25, 2026
Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network
Aug 5, 2026
Closed €1.46 (+4.3%) on Aug 6, 2026
Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments
Jul 30, 2026
Closed €1.50 (0.0%) on Jul 31, 2026
Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project
Jul 23, 2026
Closed €1.50 (0.0%) on Jul 23, 2026
Aliko Scientific Signs Memorandum of Understanding with BioBrasil for Brazilian FISH Probe Manufacturing Joint Venture
May 25, 2026
Closed €1.55 (0.0%) on May 26, 2026
Ikonisys SA on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 22 in the last 12 months · 30 in all · newest Nov 12, 2026 · oldest 2025
Where Ikonisys SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:ALIKO · Home listing · This page | Euronext | France | EUR |
| LS Exchange:A3CVR6 | LS Exchange | Germany | EUR |
| Frankfurt:9W8 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3CVR6 | Lang & Schwarz | Germany | EUR |
| Stuttgart:9W8 | Stuttgart | Germany | EUR |
Valuation
EV/sales 20.4× against a median of 1.8×: 8th lowest of 9 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €28.35M EUR
- P/E
- Loss
- EV/sales
- 20.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- 64.6%
- Operating margin
- −290.7%
- Net margin
- −302.8%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ikonisys SA · EURONEXT:ALIKO | US$26.75M | US$31.11M | n/a | 20.4× | n/a | 1.3× | −302.8% | 0.3× | n/a |
| Abingdon Health PLC · LSE:ABDX | US$28.12M | US$26.13M | n/a | 1.8× | n/a | 3.5× | −19.4% | 0.2× | n/a |
| MedMira Inc. · TSXV:MIR | US$26.91M | US$27.23M | n/a | 105× | n/a | n/a | −808.2% | n/a | 0.29 |
| BIOQUAL, Inc. · OTC:BIOQ | US$26.83M | US$42.28M | n/a | 1.1× | n/a | 0.8× | −11.0% | 1.0× | -0.01 |
| Interpace Biosciences, Inc. · OTC:IDXG | US$26.56M | US$23.63M | 1.2× | 0.6× | 21.0× | 1.1× | 58.1% | 0.0× | -0.33 |
| Microbix Biosystems Inc. · TSX:MBX | US$26.27M | US$25.96M | n/a | 2.4× | n/a | 1.6× | −31.7% | 0.3× | 0.03 |
| Bioptic Inc. · TPEX:6850 | US$26.11M | US$22.56M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | n/a |
| genOway SA · EURONEXT:ALGEN | US$25.87M | US$38.95M | 25.4× | 1.7× | 8.7× | 1.1× | 4.4% | 0.7× | n/a |
| Orientbio, Inc. · KRX:002630 | US$25.03M | −US$3.27M | 14.6× | −0.1× | −0.8× | 0.5× | 8.1% | 0.0× | n/a |
| Clever Culture Systems Limited · ASX:CC5 | US$24.62M | US$25.47M | n/a | 8.3× | n/a | 4.9× | −48.4% | 0.4× | n/a |
| CLEO Diagnostics Ltd · ASX:COV | US$24.57M | US$20.44M | n/a | n/a | n/a | 7.4× | n/a | 0.0× | n/a |
| Median of the others | US$26.19M | US$25.72M | 14.6× | 1.8× | 8.7× | 1.6× | −15.2% | 0.2× | 0.01 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.30 EUR · Analysts' mean
- EPS, year to Dec 2026
- 0.030 · 1 analyst
- Revenue, year to Dec 2026
- 2M · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Francesco Trisolini | Group CEO and for implementation of the approved industrial plan |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2025 | Nov 3, 2025 | 0.0% |
| Q2 2025 | Sep 24, 2025 | 0.0% |
| Quarter to Sep 30, 2024 | Nov 7, 2024 | −4.0% |
| Q3 2022 | Oct 27, 2022 · After close | −1.2% |
| Q1 2022 | Apr 29, 2022 · After close | −0.4% |
| Q3 2021 | Oct 29, 2021 · After close | +5.5% |
| Q2 2021 | Jul 1, 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertible notes Closed: €722,500 raised Use of proceeds: Strengthen the Group's available liquidity | Aug 24, 2026 | US$842,864 |
| Private placement of new ordinary shares Closed: €1.5M raised · €1.5 a share Buyers: Avantgarde Srl; Alberto Previtali Use of proceeds: Mainly commercial development and expanding the distributor network; also technology and product development, and regulatory and certification work | Dec 19, 2025 | US$1.76M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.39M | 1.01M | 448.6K | 935.2K | 365.1K | 99.8K | 68.4K |
| Cost of revenue | 490.8K | 295.7K | 192.7K | 183.4K | 70.6K | 27.1K | 63.7K |
| Gross profit | 897.3K | 715.4K | 255.8K | 751.8K | 28.5K | 72.8K | 4.75K |
| Research and development | 418.1K | 680.0K | 1.38M | 45.2K | 37.9K | ||
| Selling, general and administrative | 1.35M | 1.71M | 770.5K | 645.7K | 874.2K | 9.52K | 15.6K |
| Operating income | -4.04M | -3.05M | -2.19M | -2.64M | -564.2K | 204.7K | -250.9K |
| Depreciation and amortization | 2.76M | 1.28M | 1.27M | 1.08M | 80.6K | 68.2K | 70.8K |
| EBITDA | -1.28M | -1.77M | -927.4K | -1.55M | -483.7K | 272.9K | -180.0K |
| Interest expense | 304.0K | 186.3K | 73.9K | 13.5K | 5.11K | 1.77M | 1.62M |
| Income before tax | -4.20M | -3.24M | -2.27M | -2.45M | -569.3K | -1.57M | -1.87M |
| Income tax | 2.38K | 2.90K | -2 | 57.7K | 1.93K | 6.30K | 5.05K |
| Net income | -4.20M | -3.24M | -2.27M | -2.45M | -571.3K | -1.57M | -1.88M |
| Earnings per share, basic | -0.30 | -0.29 | -0.22 | -0.26 | -0.06 | -0.16 | -0.19 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.03M | 25.1K | 9.40K | 94.0K | 1.52M | 37.6K | 173.0K |
| Short-term investments | 2.24K | 35.8K | 46.8K | ||||
| Receivables | 899.8K | 651.0K | 3.21K | 24.6K | 139.1K | 29.5K | 28.8K |
| Inventory | 730.0K | 688.6K | 473.4K | 446.3K | 141.6K | ||
| Current assets | 2.66M | 1.66M | 691.1K | 693.1K | 1.88M | 70.7K | 208.8K |
| Property, plant and equipment | 10.0K | 301.1K | 70 | ||||
| Goodwill | 22.0M | 22.0M | 16.1M | 16.1M | 16.1M | 4.42M | 4.82M |
| Total assets | 26.7M | 27.4M | 20.9M | 21.7M | 22.5M | 8.08M | 8.13M |
| Accounts payable | 1.84M | 1.74M | 1.29M | 1.08M | 977.5K | 812.8K | 760.8K |
| Current liabilities | 5.55M | 3.01M | 2.30M | 1.51M | 1.24M | 2.19M | 1.76M |
| Long-term debt | 1.32M | 4.02M | 3.21M | 2.21M | 1.20M | 119.5K | 130.5K |
| Total debt | 3.25M | 4.13M | 3.40M | 2.51M | 1.24M | 198.4K | 296.7K |
| Total liabilities | 7.58M | 13.1M | 5.12M | 4.04M | 2.50M | 2.39M | 2.04M |
| Shareholders' equity | 19.1M | 14.3M | 15.7M | 17.7M | 20.0M | 5.70M | 6.09M |
| Shares outstanding | 13.9M | 11.2M | 10.5M | 9.48M | 9.48M | 9.71M | 9.71M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -1.16M | -1.33M | -914.2K | -1.14M | -781.4K | -1.52M | |
| Capital spending | -9.09K | -37.9K | -542.4K | -874.7K | -576.0K | 0 | 0 |
| Free cash flow | -1.17M | -1.37M | -1.46M | -2.01M | -1.36M | -1.52M | |
| Cash from investing | -301.6K | -67.6K | -545.2K | -884.2K | -636.6K | -239.6K | |
| Cash from financing | 2.36M | 1.41M | 1.37M | 599.1K | 2.90M | 1.62M | |
| Share buybacks | 469.5K | 3.03M | -170.7K | ||||
| Change in cash | 1.00M | 15.7K | -84.6K | -1.42M | 1.48M | -135.4K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Aliko Scientific announces the results of its Ordinary Annual and Extraordinary General Meeting of October 30, 2026 | Nov 5, 2026 | Meeting notice | Euronext |
Cap table
Built by 6ix from Ikonisys SA’s releases · as of Aug 24, 2026
- Common shares
- 15,825,785
- Fully diluted
- 15,825,785
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 15,825,785 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 15,825,785 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Francesco Trisolini | Group CEO and for implementation of the approved industrial plan · Since at least Feb 17, 2026 |
Log in to ask 6ix AI your own questions about Ikonisys SA.